---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-015517"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T04:36:20.953213+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Pulse Biosciences Q1 net loss widens to $16.8M; cash $119.3M; clinical milestones set

## Summary
- GAAP net loss of $16.8M vs $10.1M in Q1 2024; non-GAAP net loss $11.4M vs $8.1M.
- Cash and equivalents $119.3M as of March 31, 2025, down from $118.0M at Dec 31, 2024.
- Costs and expenses $18.0M, up $7.4M YoY, driven by stock-based comp and organization expansion.
- On track to launch nsPFA Percutaneous Electrode System in H2 2025; U.S. IDE for cardiac surgery and catheter systems expected mid-2025.
- Treated 100 patients in Europe with nsPFA 360° catheter; data presented at HRS 2025.

## SEC filing metadata
- accession: 0001437749-25-015517
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000143774925015517/0001437749-25-015517-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000143774925015517/plse20250506_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-015517
- JSON: https://secwatch.observer/filing/0001437749-25-015517.json
- Plain text: https://secwatch.observer/filing/0001437749-25-015517.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.